5-[5-(1-morpholin-4-yl-2,3-dihydro-1H-inden-4-yl)-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile | 1307872-52-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[5-(1-morpholin-4-yl-2,3-dihydro-1H-inden-4-yl)-1,3-thiazol-2-yl]-2-propan-2-yloxybenzonitrile
• CAS: 1307872-52-1
• 化学式: C₂₆H₂₇N₃O₂S
• 分子量: 445.585
• InChiKey: NHWOKKMQLRQSFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  86.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS
  申请人：Boehm Marcus F.

  公开号：US20150299179A1

  公开（公告）日：2015-10-22

  Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

  提供了选择性调节鞘氨醇1磷酸受体的化合物，包括调节S1P受体亚型1的化合物。还提供了此类化合物的手性合成方法。与治疗或预防疾病、不良状况和紊乱相关的用途、治疗方法或预防方法以及制备包括创新化合物的创新组合物的方法被提供，其中调节鞘氨醇1磷酸受体在医学上是适用的。
• US8507538B2
  申请人：——

  公开号：US8507538B2

  公开（公告）日：2013-08-13
• US9481659B2
  申请人：——

  公开号：US9481659B2

  公开（公告）日：2016-11-01
• [EN] SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES SÉLECTIFS DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE
  申请人：RECEPTOS INC

  公开号：WO2012158550A2

  公开（公告）日：2012-11-22

  Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.